Phase 2 AMETHYST findings show continued improvements in skin redness and clinician- and patient-reported outcomes with litifilimab.
News|Slideshows|February 28, 2025
SLIDESHOW: A Look at 5 Rare Skin Conditions
Listen
0:00 / 0:00
Today, Dermatology Times recognizes Rare Disease Day in an effort to amplify the voices of the over 300 million individuals affected by rare diseases.
Advertisement
References
- Rare Disease Day. What is Rare Disease Day? Accessed February 26, 2025.
https://www.rarediseaseday.org/what-is-rare-disease-day/ - Schmieder SJ, Sathe NC, Rosario-Collazo JA. Darier Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; November 30, 2023.
- Khanna D, Bardhan A. Epidermolysis bullosa. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 11, 2024.
- Konstantinou MP, Krasagakis K. Benign familial pemphigus (Hailey-Hailey Disease). In: StatPearls. Treasure Island (FL): StatPearls Publishing; August 14, 2023.
- Ngan V. Netherton syndrome. DermNet. Published 2005. Accessed February 26, 2025.
https://dermnetnz.org/topics/netherton-syndrome - Ingold CJ, Sathe NC, Khan MAB. Pemphigus vulgaris. In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 1, 2024.
Advertisement
Related to this article
A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.
At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.
Gaurav Singh, MD, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.
A 2026 study links Agent Orange exposure to higher odds of acral melanoma in US veterans, highlighting the importance of early detection.
Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermatology Times Monthly FDA and Pipeline Review: October 2026
2
Updated HS Guidelines Emphasize Biologics and Early Intervention
3
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
4
Phase 3 Trial Supports Risankizumab for Pediatric Psoriasis
5